Abstract
Rhabdomyosarcomas secrete high levels of insulin-like growth factor-II, suggesting this autocrine growth factor plays a major role in the unregulated growth of this childhood cancer. Treatment of Rh30 rhabdomyosarcoma cells with insulin-like growth factor binding protein-6 (IGFBP-6; 1000 ng/ml), which binds insulin-like growth factor-II with high affinity, inhibited growth in vitro (p < 0.001). Co-incubation of cells with rapamycin (1.56 ng/ml), an inhibitor of p70 S6 kinase, and IGFBP-6 (200 ng/ml) resulted in a significant reduction in Rh30 cell number compared to rapamycin or IGFBP-6 alone (p < 0.05 for both). Co-treatment of Rh30 cells with CCI-779 (5 and 50 ng/ml), an ester analogue of rapamycin, and IGFBP-6 (200 or 1000 ng/ml) also inhibited growth in vitro relative to CCI-779 alone (p < 0.01 and p < 0.001, respectively). In a nude mouse model, xenografts of Rh30 cells transfected with a recombinant vector encoding IGFBP-6 (phBP6-E3) showed delayed growth relative to vector control xenografts (27 days vs. 19 days to reach an average tumour volume of 0.5 cm3; p < 0.001). Treatment with CCI-779 (10 mg/kg) of mice inoculated with vector control xenografts, also delayed growth (to 31 days; p = 0.0055) relative to untreated mice with vector control xenografts. Co-treatment with CCI-779 (10 mg/kg) reduced phBP6-E3 transfected xenograft growth even further (to 45 days) compared to vector control xenografts (p < 0.001, day 33). CCI-779 thus acts additively with IGFBP-6 to reduce rhabdomyosarcoma growth both in vitro and in vivo.
Key words
Cancer - Xenograft - Insulin-like Growth Factor
References
-
1
Jones J I, Clemmons D R.
Insulin-like growth factors and their binding proteins: biological actions.
Endocr Rev.
1995;
16
3-34
-
2
Bach L A, Rechler M M.
Insulin-like growth factors and diabetes.
Diabetes Metab Rev.
1992;
8
229-257
-
3
Bach L A.
Insulin-like growth factor binding protein-6: the ”forgotten“ binding protein?.
Horm Metab Res.
1999;
31
226-234
-
4
Daughaday W H.
The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors.
Endocrinology.
1990;
127
1-4
-
5
El-Badry O M, Minniti C P, Kohn E C, Houghton P J, Daughaday W H, Helman L J.
Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors.
Cell Growth Differ.
1990;
1
325-331
-
6
Minniti C P, Tsokos M, Newton W A, Helman L J.
Specific expression of insulin-like growth factor-II in rhabdomyosarcoma tumor cells.
Am J Clin Pathol.
1994;
101
198-203
-
7
Gallicchio M A, Kneen M, Hall C, Scott A M, Bach L A.
Overexpression of insulin-like growth factor binding protein-6 inhibits rhabdomyosarcoma growth in vivo
.
Int J Cancer.
2001;
94
645-651
-
8
Shamji A F, Nghiem P, Schreiber S L.
Integration of growth factor and nutrient signaling: implications for cancer biology.
Mol Cell.
2003;
12
271-280
-
9
Thimmaiah K N, Easton J, Huang S, Veerka K A, Germain G S, Harwood F C, Houghton P J.
Insulin-like growth factor-I-mediated protection from rapamycin-induced apoptosis is independent of Ras-ErkI-Erk2 and phosphatidylinosiyol 3’-kinase-Akt signaling pathways.
Cancer Res.
2003;
63
364-374
-
10
Wan X, Helman L J.
Effect of insulin-like growth factor II on protecting myoblast cells against cisplatin-induced apoptosis through the p70 S6 kinase pathway.
Neoplasia.
2002;
4
400-408
-
11
Hosoi H, Dilling M B, Shikata T, Liu L N, Shu L, Ashmun R A, Germain G S. et al .
Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells.
Cancer Res.
1999;
59
886-894
-
12
Rosenwald I B, Kaspar R, Rousseau D, Gerhrke L, Leboulch P, Chen J-J, Schmidt E V. et al .
Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels.
J Biol Chem.
1995;
270
21 176-21 180
-
13
Nielsen F C, Ostergaard L, Nielsen J, Christiansen J.
Growth-dependent translation of IGF-II mRNA by a rapamycin-sensitive pathway.
Nature.
1995;
377
358-362
-
14
Eng C P, Sehgal S N, Vezina C.
Activity of rapamycin (AY-22,989) against transplanted tumors.
J Antibiot (Tokyo).
1984;
37
1231-1237
-
15
Dudkin L, Dilling M B, Cheshire P J, Harwood F C, Hollingshead M, Arbuck S G, Travis R. et al .
Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.
Clin Cancer Res.
2001;
7
1758-1764
-
16
Ciardiello F, Bianco R, Damiano V, de Lorenzo S, Pepe S, de Placido S, Fan Z. et al .
Antitumor activity of sequential treatment of topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
Clin Cancer Res.
1999;
5
909-916
-
17
Geoerger B, Kerr K, Tang C-B, Fung K-M, Powell B, Sutton L N, Phillips P C. et al .
Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medullablastoma models as single agent and in combination chemotherapy.
Cancer Res.
2001;
61
1527-1532
-
18
Dilling M B, Dias P, Shapiro D N, German G S, Johnson R K, Houghton P J.
Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibiton of signaling via the type I insulin-like growth factor receptor.
Cancer Res.
1994;
54
903-907
-
19
Neumann G M, Bach L A.
The N-terminal disulfide linkages of human insulin-like growth factor-binding protein-6 (hIGFBP-6) and hIGFBP-1 are different as determined by mass spectrometry.
J Biol Chem.
1999;
274
14 587-14 594
-
20
Bach L A, Hsieh S, Brown A L, Rechler M.
Recombinant human insulin-like growth factor (IGF) binding protein-6 inhibits IGF-II-induced differentiation of L6A1 myoblasts.
Endocrinology.
1994;
135
2168-2176
-
21
Huseby R A, Maloney T M, McGrath C M.
Evidence for a direct growth-stimulating effect of estradiol on human MCF-7 cells in vivo.
.
Cancer Res.
1984;
44
2654-2659
-
22
Hosoi H, Dilling M B, Liu L N, Danks M K, Shikata T, Sekulic A, Abraham R T. et al .
Studies on the mechanism of resistance to rapamycin in human cancer cells.
Mol Pharamacol.
1998;
54
815-824
-
23
Shi Y, Frankel A, Radvaryi L G, Penn L Z, Miller R G, Mills G B.
Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro.
.
Cancer Res.
1995;
55
1982-1988
-
24
Muthukkumar S, Ramesh T M, Bondada S.
Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells.
Transplantation.
1995;
60
264-270
-
25
Dilling M B, Germain G S, Dudkin L, Jayaraman A L, Zhang X, Harwood F C, Houghton P J.
4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin.
J Biol Chem.
2002;
277
13 907-13 917
-
26
Graves L M, Bornfeldt K E, Argast G M, Krebs E G, Kong X, Lin T A, Lawrence J C, Jr.
cAMP- and rapamycin-sensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-I in aortic smooth muscle cells.
Proc Natl Acad Sci USA.
1995;
92
7222-7226
-
27
Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns C J. et al .
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.
Nat Med.
2002;
8
128-135
-
28 Alexander J W, Raymond E, Depenbrock H, Mekaldi S, Angevin E, Pailler C, Hanauske A. et al .CCI-779, a new rapamycin analog, has antitumour activity at doses inducing only mild cutaneous effects and mucositis: early results of an ongoing phase I study. In: Proceedings of the 10th AACR-NCI-EORTC International Conference, 1999. Washington, USA; 1999
-
29 Hidalgo M, Rowinsky E K, Erlichman C, Drengler R, Marshall B, Adjei A, Hammond L. et al .Phase I and pharmacological study of CCI-779, a cell cycle inhibitor. In: Proceedings of the 11th AACR-NCI-EORTC symposium; 2000. Amsterdam, The Netherlands; 2000
L. Bach
Department of Medicine, University of Melbourne
Austin Hospital · Studley Rd. · Heidelberg · Victoria, 3084 · Australia
Phone: +61(39496)3581
Fax: +61(39457)5485
Email: l.bach@unimelb.edu.au
